ASH: In next BCMA myeloma race, Gracell dazzles with 100% response rate as Pfizer, BMS place their bets

Five years after Legend Biotech made a splash with an initial 100% tumor response rate for what would later become Johnson & Johnson-partnered Carvykti, another Chinese company has repeated the same remarkable data for its BCMA-targeted CAR-T therapy, this time in an earlier multiple myeloma setting.